CC-401 (CC401) is a potent, specific, 2nd generation and ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with potential antineoplastic activity.

Tanzisertib HCl (also known as CC-930) is a potent, specific and and orally bioavailable JNK1/JNK2/JNK3 inhibitor that has the potential to be used for the treatment of fibrotic and infammatory indications.

AS602801 (also known as Bentamapimod and PGL5001) is a novel, potent and ATP-competitive JNK (c-Jun N-terminal Kinase) inhibitor with IC50 values of 80 nM, 90 nM, and 230 nM for JNK1, JNK2, and JNK3, respectively.

IQ-1S is a potent and selective c-Jun N-Terminal Kinase Inhibitor.

WHI-P258 is a potent and selective Janus kinase 3 (JAK3) inhibitor discovered from homology modeling.

DB07268 is is a potent and selective JNK1 inhibitor.

RPI-1 is an ATP-dependent RET kinase inhibitor.

Tanzisertib (formerly known as CC-930, JNK-930, JNKI-1, CC 930) is a potent, specific and and orally bioavailable JNK1/JNK2/JNK3 inhibitor that has the potential to be used for the treatment of fibrotic and infammatory indications.

KB-R7943 mesylate, the mesylate salt of KB-R-7943, is a novel and potent reverse Na(+) /Ca(2+) exchanger (NCX(rev)) with neuroprotective action.

Anisomycin (Wuningmeisu C, NSC76712, AI3-50846, Flagecidin), a naturally occuring bacterial antibiotic isolated from Streptomyces griseolus, is a novel, potent and specific activator (agonist) of JNK (c-Jun N-terminal Kinase) with potential antineoplastic activity.